Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia

NCT01585272 | Completed Phase 4 Results

• 1 other identifier: CENA713DTW04
• Study Type: interventional
• Target: 121
• Locations: 1 country
• Sites: 4

Brief Summary

This phase IIIb study is intended to implement a consistent treatment way for switching to Exelon transdermal patch from oral formulation of rivastigmine to stress the importance of (1) advantages of transdermal patch over conventional oral therapies: smooth drug delivery with reduced side effects;(2) encourage treatment compliance in the Alzheimer's dementia setting. This study is a single-arm, treatment-switched design. Eligible patients, who are under Exelon capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to patch for 48 weeks maintenance treatment. During the maintenance period, the treatment will be initiated with Exelon Patch 4.6 mg/24 hours (Exelon Patch 5 cm\^2) for the first 24 weeks and the dose will be escalated to Exelon Patch 9.5 mg/24 hours (Exelon Patch 10 cm\^2) for another 24 weeks if well tolerated. Visits to assess safety are scheduled at baseline, 3 days, 1 week and 2 weeks after the first treatment switch, every 4 weeks until Week 40, and at the end of study (Week 52). The assessment to address the primary objective will focus on the safety of treatment switching (Week 0\~28); however the safety assessment will be performed during the whole study period.

Conditions

Alzheimer's Dementia

Keywords

Alzheimer's dementia, AD

Outcome Measures

Primary Outcomes (1)

• Number of Patients With Adverse Events, Serious Adverse Events, and Death

  The overall rate of adverse events reported from initiation through the first 28-week treatment period

  Baseline through week 28

Secondary Outcomes (4)

• Change From Baseline in Mini-Mental Status Examination (MMSE)

  Baselin, week 16, 28 and 52

• Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

  Baseline, week 16, 28 and 52

• The Discontinuation Rate Due to the Treatment Switching From Oral Capsule to Rivastigmine Patch Treatment

  Baseline through week 52

• Percentage of Patients Successfully Titrated to Rivastigmine Patch 10 cm^2

  Baseline through week 52

Study Arms (1)

Rivastigmine

EXPERIMENTAL

Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.

Drug: ENA713

Interventions

ENA713 DRUG

Also known as: Rivastigmine

Rivastigmine

Eligibility Criteria

• Age: 50 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• With diagnosis of mild to moderate Alzheimer's disease.
• Mini-Mental Status Examination score of 10-26 within 3 months before starting oral rivastigmine treatment.
• A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria. The brain scan (magnetic resonance imaging (MRI) or computed tomography (CT) used for establishing that these criteria are met must have been available on the source document within one year prior to study participation.
• Patients who are currently taking or planned to receive Exelon 3 mg capsule twice-daily treatment.
• Written informed consent must be obtained before any assessment is performed.
• If female, must be surgically sterile or at least one year post-menopausal.
• Sufficient education to read, write, and communicate effectively.
• Capable of complying with the requirements of the study

You may not qualify if:

• Any advanced, severe or unstable disease that could interfere with study evaluation or completion or put patient at special risk.
• Any medical or neurological condition other than AD that could explain the patient's dementia (e.g., abnormal thyroid function tests, Vitamin B12 or folate deficiency, posttraumatic conditions, Huntington's disease, Parkinson's disease, syphilis).
• Active uncontrolled peptic ulceration, or gastrointestinal bleeding, within the previous 3 months prior to visit 1.
• A current diagnosis of active, uncontrolled seizure disorder.
• A history within the past year or current diagnosis of cerebrovascular disease (e.g., stroke, transient ischemic attacks, aneurysms).
• Bradycardia (\< 50 beats per minute), sick sinus syndrome, conduction deficits (S-A block, second or third degree A-V block)
• Severe or unstable cardiovascular disease.
• Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
• History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes, or other components of the formulation.
• Current diagnosis of a systemic active skin disorder or lesion that would prevent accurate assessment of the adhesion and skin irritation potential of the patch.
• Previous lack of efficacy with cholinesterase inhibitors.
• History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. Patients with history of malignancy yet have been treated and defined as complete remission for more than 5 years are not excluded from study participation.
• Pregnant or nursing (lactating) women.
• Concurrently treated with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol 2 weeks before the start of study drug and during the treatment period.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (4)

Novartis Investigative Site

Taichung, Taiwan ROC, Taiwan

Location

Novartis Investigative Site

Taipei, Taiwan, ROC, 112, Taiwan

Location

Novartis Investigative Site

Taichung, 40447, Taiwan

Location

Novartis Investigative Site

Taipei, 10002, Taiwan

Location

MeSH Terms

Conditions

Alzheimer Disease

Interventions

Rivastigmine

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Phenylcarbamates; Carbamates; Acids, Acyclic; Carboxylic Acids; Organic Chemicals

Results Point of Contact

• Title: Study Director
• Organization: Novartis Pharmaceutical

862-778-8300

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 23, 2012
• First Posted: April 25, 2012
• Study Start: August 1, 2012
• Primary Completion: June 1, 2015
• Study Completion: June 1, 2015
• Last Updated: April 18, 2018
• Results First Posted: November 10, 2016

Record last verified: 2018-04

Locations

TW (4)